Pharming (PHAR) Cash & Equivalents (2018 - 2026)

Pharming (PHAR) has 9 years of Cash & Equivalents data on file, last reported at $158.3 million in Q2 2026.

• Quarterly Cash & Equivalents rose 71.87% year-over-year to $158.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $158.3 million (up 71.87% YoY) and the FY2025 annual result came in at $145.3 million, up 9587.0% from the prior year.
• Cash & Equivalents grew to $158.3 million in Q2 2026, from $52.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $207.3 million in Q4 2022 to a low of $1.5 million in Q4 2024.
• A 5-year average of $123.7 million and a median of $138.8 million in 2025 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 106934.94% in 2022, down 99.91% in 2022.
• Tracing PHAR's Cash & Equivalents over 5 years: stood at $207.3 million in 2022, then slumped by 70.22% to $61.7 million in 2023, then slumped by 97.57% to $1.5 million in 2024, then jumped by 9587.0% to $145.3 million in 2025, then advanced by 8.93% to $158.3 million in 2026.
• The last three Cash & Equivalents figures came in at $158.3 million (Q2 2026), $52.4 million (Q1 2026), and $145.3 million (Q4 2025), per Business Quant data.